Promoted Content Promoted Content


Find Immunology Drugs in Phase III Clinical Development in FRANCE


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sutimlimab

            Therapeutic Area: Immunology Product Name: BIVV009

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bioverativ Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2021


            The CADENZA trial is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sutimlimab in patients with CAD without a recent history of blood transfusion (within the past 6 months).